These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 9059069

  • 1. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T, Gondo H, Uchida N, Matsuo I, Takenaka K, Tanimoto K, Otsuka T, Minematsu T, Minamishima Y, Niho Y.
    Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
    [Abstract] [Full Text] [Related]

  • 2. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A, van Lint MT, Tedone E, Moro F, Sanna MA, Longren M, Trespi G, Frassoni F, Occhini D, Gualandi F.
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
    Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H, Tamura A, Fujimori Y, Takemoto Y, Kanamaru A, Kakishita E.
    Bone Marrow Transplant; 1997 Nov; 20(9):801-3. PubMed ID: 9384487
    [Abstract] [Full Text] [Related]

  • 4. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Avery RK, Bolwell BJ, Yen-Lieberman B, Lurain N, Waldman WJ, Longworth DL, Taege AJ, Mossad SB, Kohn D, Long JR, Curtis J, Kalaycio M, Pohlman B, Williams JW.
    Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
    [Abstract] [Full Text] [Related]

  • 5. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K, Groll AH, Kuehn J, Vormoor J.
    Klin Padiatr; 2006 Dec; 218(3):180-4. PubMed ID: 16688677
    [Abstract] [Full Text] [Related]

  • 6. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, Ganser A, Hertenstein B.
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [Abstract] [Full Text] [Related]

  • 7. [Ganciclovir-resistant cytomegalovirus infection: 2 cases with different clinical impact].
    Reusser P, Hostettler B, Attehbofer R.
    Schweiz Med Wochenschr; 1996 Oct 19; 126(42):1779-84. PubMed ID: 8966510
    [Abstract] [Full Text] [Related]

  • 8. [Chronic myelocytic leukemia associated with cytomegalovirus induced sialoadenitis after unrelated allogeneic bone marrow transplantation].
    Yoshida M, Ueda S, Harano H, Yamazaki E, Kato K, Tanabe J, Okamoto R, Ogawa K, Mohri H, Okubo T, Sasaki S, Matsuzaki M, Nakatani Y, Chiba N.
    Rinsho Ketsueki; 1996 Jan 19; 37(1):46-52. PubMed ID: 8683867
    [Abstract] [Full Text] [Related]

  • 9. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S, Bertilson S, Tedone E, Van Lint MT, Trespi G, Mordini N, Berisso G, Gualandi F, Lamparelli T, Figari O, Benvenuto F, Raiola AM, Bacigalupo A.
    Bone Marrow Transplant; 2000 Jul 19; 26(1):23-9. PubMed ID: 10918402
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
    Takami A, Mochizuki K, Ito S, Sugimori C, Yamashita T, Asakura H, Okumura H, Nakao S.
    Transplant Proc; 2007 Jul 19; 39(1):237-9. PubMed ID: 17275512
    [Abstract] [Full Text] [Related]

  • 11. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J, Casper K, Smallwood G, Stieber A, Fasola C, Lehneman J, Heffron T.
    Liver Transpl; 2007 Oct 19; 13(10):1396-400. PubMed ID: 17902124
    [Abstract] [Full Text] [Related]

  • 12. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
    Bacigalupo A, Bregante S, Tedone E, Isaza A, Van Lint MT, Moro F, Trespi G, Occhini D, Gualandi F, Lamparelli T, Marmont AM.
    Bone Marrow Transplant; 1996 Nov 19; 18 Suppl 2():110-4. PubMed ID: 8932810
    [Abstract] [Full Text] [Related]

  • 13. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M, Burroughs AK, Sweny P, Hassan-Walker AF, Okwuadi S, Sabin C, Amooty G, Brown VS, Grace SC, Emery VC, Griffiths PD.
    J Infect Dis; 2004 Apr 15; 189(8):1355-61. PubMed ID: 15073671
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec 15; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

  • 15. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E, Kallas WM, Fishman JA.
    Clin Infect Dis; 2002 May 15; 34(10):1337-41. PubMed ID: 11981729
    [Abstract] [Full Text] [Related]

  • 16. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ, Zaas AK, Hanson KE, Palmer SM.
    J Heart Lung Transplant; 2007 Dec 15; 26(12):1286-92. PubMed ID: 18096480
    [Abstract] [Full Text] [Related]

  • 17. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T, Morishima Y, Kitaori K, Kato C, Sao H.
    Int J Hematol; 1999 Aug 15; 70(2):119-26. PubMed ID: 10497851
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation.
    Kaulfersch W, Urban C, Hauer C, Lackner H, Gamillscheg A, Slavc I, Langmann G.
    Bone Marrow Transplant; 1989 Sep 15; 4(5):587-9. PubMed ID: 2551437
    [Abstract] [Full Text] [Related]

  • 19. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation.
    Singhal S, Mehta J, Powles R, Treleaven J, Horton C, Carrington D, Tryhorn Y, Jameson B.
    Bone Marrow Transplant; 1995 May 15; 15(5):777-81. PubMed ID: 7670405
    [Abstract] [Full Text] [Related]

  • 20. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep 15; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.